Sobi’s shareholders receive recommended public cash offer from Advent and GIC
Sobi is advised by Mannheimer Swartling in relation to the recommended public cash offer to the shareholders in Sobi by Advent and GIC, through Agnafit Bidco.
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications.
The offer values Sobi at approximately SEK 69.4 billion.